DK3551633T3 - Substituerede pyrazoloazepin-4-oner og anvendelse deraf som phosphodiesterasehæmmere - Google Patents

Substituerede pyrazoloazepin-4-oner og anvendelse deraf som phosphodiesterasehæmmere Download PDF

Info

Publication number
DK3551633T3
DK3551633T3 DK16809388.8T DK16809388T DK3551633T3 DK 3551633 T3 DK3551633 T3 DK 3551633T3 DK 16809388 T DK16809388 T DK 16809388T DK 3551633 T3 DK3551633 T3 DK 3551633T3
Authority
DK
Denmark
Prior art keywords
ones
phosphodiesterase inhibitors
pyrazoloazepin
substituted
substituted pyrazoloazepin
Prior art date
Application number
DK16809388.8T
Other languages
Danish (da)
English (en)
Inventor
Xifu Liang
Jens Larsen
Peter Andersen
Simon Feldbæk Nielsen
Original Assignee
Union Therapeutics As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Union Therapeutics As filed Critical Union Therapeutics As
Application granted granted Critical
Publication of DK3551633T3 publication Critical patent/DK3551633T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK16809388.8T 2016-12-12 2016-12-12 Substituerede pyrazoloazepin-4-oner og anvendelse deraf som phosphodiesterasehæmmere DK3551633T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2016/080548 WO2018108230A1 (en) 2016-12-12 2016-12-12 Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
DK3551633T3 true DK3551633T3 (da) 2021-06-28

Family

ID=57539258

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16809388.8T DK3551633T3 (da) 2016-12-12 2016-12-12 Substituerede pyrazoloazepin-4-oner og anvendelse deraf som phosphodiesterasehæmmere

Country Status (8)

Country Link
US (1) US10906915B2 (https=)
EP (1) EP3551633B1 (https=)
JP (1) JP6850886B2 (https=)
CN (1) CN110088108B (https=)
DK (1) DK3551633T3 (https=)
ES (1) ES2875128T3 (https=)
RU (1) RU2762279C2 (https=)
WO (1) WO2018108230A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3551632B1 (en) * 2016-12-12 2024-06-12 UNION therapeutics A/S Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors
DK3642210T3 (da) 2017-06-20 2024-12-09 Union Therapeutics As Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
PT3724196T (pt) 2017-12-15 2023-01-13 Union Therapeutics As Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2803299B1 (fr) * 2000-01-05 2004-09-17 Warner Lambert Co NOUVELLES PYRAZOLO [4,3-e] DIAZEPINES SUBSTITUEES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
WO2004098520A2 (en) 2003-05-01 2004-11-18 Irm Llc Compounds and compositions as protein kinase inhibitors
TW200745106A (en) * 2005-10-03 2007-12-16 Astrazeneca Ab Chemical compounds
ES2372320T3 (es) 2006-11-15 2012-01-18 Vertex Pharmceuticals Incorporated Compuestos útiles como inhibidores de proteínas quinasas.
CA2676933C (en) * 2007-02-28 2015-09-29 Leo Pharma A/S Novel phosphodiesterase inhibitors
GB0704652D0 (en) 2007-03-09 2007-04-18 Syngenta Participations Ag Novel herbicides
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos

Also Published As

Publication number Publication date
CN110088108A (zh) 2019-08-02
RU2019121006A (ru) 2021-01-12
US20200010477A1 (en) 2020-01-09
US10906915B2 (en) 2021-02-02
RU2019121006A3 (https=) 2021-01-12
JP6850886B2 (ja) 2021-03-31
JP2020500920A (ja) 2020-01-16
CN110088108B (zh) 2024-06-14
RU2762279C2 (ru) 2021-12-17
EP3551633A1 (en) 2019-10-16
EP3551633B1 (en) 2021-03-31
ES2875128T3 (es) 2021-11-08
WO2018108230A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
IL269196A (en) Novel inhibitors
IL263586A (en) Inhibitors of the menin-mll interaction
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
IL280863A (en) Autotaxin inhibitors and uses thereof
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3149001T3 (da) Hidtil ukendte pyrazolopyrimidinderivater og deres anvendelse som MALT1-hæmmere
DK3442972T3 (da) Bromdomænehæmmere
DK3663290T3 (da) Polymethinforbindelser og anvendelse deraf som fluorescerende markører
DK3221306T3 (da) Heteroarylforbindelser som irak-inhibitorer og anvendelser deraf
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3233863T3 (da) Kondenserede ringheteroarylforbindelser og anvendelse deraf som trk-hæmmere
DK3310784T3 (da) Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3538528T3 (da) Pyrrolamider som alpha v-integrinhæmmere
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf
DK3313833T3 (da) Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase
DK3341379T3 (da) EZH2-hæmmere
DK3630744T3 (da) Pyrazol-magl-inhibitorer
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
EP3600301A4 (en) KDM4 INHIBITORS
DK3724196T3 (da) Substituerede azetidindihydrothienopyridiner og anvendelse deraf som phosphodiesterasehæmmere
EP3615525C0 (en) PYRROLE DERIVATIVES AS PLK1 INHIBITORS